Nafarelin

Medical uses

Nafarelin is approved and used in the treatment of endometriosis and precocious puberty. It is also used in the treatment of uterine fibroids. The medication is used to control ovarian stimulation in in vitro fertilization (IVF). Nafarelin is used as a puberty blocker in transgender youth and to suppress testosterone levels in transgender women. Nafarelin can also be used to treat hirsutism and polycystic ovary syndrome by lowering gonadotropin and androgen levels. It is effective in the treatment of benign prostatic hyperplasia.

Dosages

Nafarelin is used to treat precocious puberty at a dosage of 1,600 to 1,800 μg per day. The 1,600 μg/day dosage is achieved by two sprays (400 μg total) into each nostril in the morning (four sprays, 800 μg total) and two sprays (400 μg total) into each nostril in the evening (four sprays, 800 μg total). If 1,600 μg/day is insufficient for adequate pubertal suppression, the 1,800 μg/day dosage can be used instead. This is achieved by three sprays (600 μg total) into alternating nostrils three times per day (nine sprays per day total). When administering the sprays, the head should be tilted back slightly and 30 seconds should elapse between each spray. A bottle of nafarelin nasal spray (brand name Synarel) lasts for about 7 days at a dosage of 1,600 μg/day.

Nafarelin is used to treat endometriosis at lower dosages of 400 to 800 μg per day. This is achieved by one or two sprays (200 or 400 μg total) into alternating nostrils once in the morning and once in the evening (two to four sprays per day total). A bottle of nafarelin nasal spray (brand name Synarel) lasts for about 30 days at a dosage of 400 μg/day.

Available forms

Nafarelin is available in the form of a 0.2% nasal spray for use one, two, or three times per day. Each bottle of nafarelin nasal spray (brand name Synarel) contains about 60 sprays delivering approximately 200 μg nafarelin in 100 μL solution per actuation. Nafarelin is not available for use by any other routes than intranasal administration.

Side effects

Side effects of nafarelin are related to sex hormone deficiency and include hot flashes, vaginal dryness, headaches, mood changes, and sexual dysfunction. Nafarelin causes erectile dysfunction in more than half of men with benign prostatic hyperplasia treated with it. Some people may experience acne, muscle pain, reduced breast size, and nasal irritation. These side effects are reversible and should resolve after stopping the medication. There is a case report of severe hyperkalemia during nafarelin therapy in a woman with uterine fibroids. The mechanism is unknown.

Pharmacology

Pharmacodynamics

Nafarelin is a GnRH agonist, or an agonist of the GnRH receptor, the biological target of GnRH. It works by continuously activating the GnRH receptor, which results in profound desensitization of the receptor such that it becomes non-functional. As a result, nafarelin suppresses the GnRH-induced secretion of the gonadotropins, luteinizing hormone and follicle-stimulating hormone, from the pituitary gland. This, in turn, results in profound suppression of gonadal sex hormone production, as well as reversible suppression of fertility.

Pharmacokinetics

The bioavailability of nafarelin with intranasal administration is 2.8% on average, with a range of 1.2 to 5.6%. The plasma protein binding of nafarelin is 80%. It is metabolized primarily by peptidases and not by cytochrome P450 enzymes. The elimination half-life of nafarelin is 2.5 to 3.0 hours by intranasal administration, whereas the half-life of nafarelin and its metabolites by subcutaneous injection is 85.5 hours. Nafarelin is eliminated 44 to 55% in urine and 18.5 to 44.2% in feces.

Chemistry

Nafarelin is a GnRH analogue, or a synthetic analogue of GnRH. It is a decapeptide and is also known as [6-D-(2-naphthyl)alanine]-GnRH. Nafarelin is marketed for medical use in both its free base (nafarelin) and acetate salt (nafarelin acetate) forms.

History

Nafarelin was introduced for medical use in 1990.

Society and culture

Generic names

Nafarelin is the generic name of the drug and its and , while nafaréline is its and nafarelin acetate is its , , and . It is also known by its former developmental code name RS-94991 or RS-94991-298.

Brand names

The major brand names of nafarelin are Synarel and Synarela. It has also been marketed under a number of other brand names including Synrelin, Synrelina, Nafarelil 0.2%, and Nasanyl 0.2%.

Availability

Nafarelin is available widely throughout the world, including in the United States, Canada, the United Kingdom, Ireland, other European countries, Australia, Israel, Argentina, Brazil, Mexico, and Japan.

References

References

1. (April 1990). "Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions". Drugs.
2. "Synarel® (nafarelin acetate) nasal solution".
3. (June 2000). "Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature". The Journal of Reproductive Medicine.
4. (October 2011). "Gonadotropin releasing hormone agonists: Expanding vistas". Indian Journal of Endocrinology and Metabolism.
5. (26 June 2017). "Peptide-based Drug Discovery: Challenges and New Therapeutics". Royal Society of Chemistry.
6. (17 August 2013). "Nasal Physiology and Pathophysiology of Nasal Disorders". Springer Science & Business Media.
7. (December 1989). "Treatment of uterine leiomyomas and hirsutism with nafarelin". The Journal of Reproductive Medicine.
8. (2001). "Arzneimittelwirkungen". Wissenschaftliche Verlagsgesellschaft.
9. (1996). "The neurochemistry of the GnRH pulse generator". Acta Neurobiologiae Experimentalis.
10. (2018). "Pediatric Endocrinology". Springer.
11. (June 2016). "Gender Incongruity in Children With and Without Disorders of Sexual Differentiation". Endocrinology and Metabolism Clinics of North America.
12. (June 2014). "The peripubertal gender-dysphoric child: puberty suppression and treatment paradigms". Pediatric Annals.
13. (February 2013). "Management of transgenderism". JAMA.
14. (May 2010). "Endocrine treatment of transsexuals: assessment of cardiovascular risk factors". Expert Review of Endocrinology & Metabolism.
15. (June 1988). "GnRH agonists-antagonists--clinical applications". European Journal of Obstetrics, Gynecology, and Reproductive Biology.
16. (24 January 2012). "Foye's Principles of Medicinal Chemistry". Lippincott Williams & Wilkins.
17. (2009). "Sexual Function in the Prostate Cancer Patient". Humana Press.
18. DailyMed: [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6 Synarel – nafarelin acetate spray]
19. (February 1996). "Severe hyperkalaemia with nafarelin". Lancet.
20. (14 June 2017). "Clinical Reproductive Medicine and Surgery: A Practical Guide". Springer.
21. (1993). "The role of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation". European Urology.
22. "Drugs@FDA: FDA-Approved Drugs".
23. (January 1991). "Gonadotropin-releasing hormone and its analogues". The New England Journal of Medicine.
24. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
25. (2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis.
26. (6 December 2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Science & Business Media.
27. "Nafarelin nasal Uses, Side Effects & Warnings".